All AbMole products are for research use only, cannot be used for human consumption.
WYE-125132 is a highly potent, ATP-competitive and specific mTOR kinase inhibitor with an IC50 of 0.19 nM. WYE-125132 blocked the activity of the both of mTORC1 and mTORC2 in various models of cancer in vitro and in vivo. WYE-125132 is 5,000-fold more selective than PI3Ks. Moreover, WYE-125132 completely blocked amino acid-induced phosphorylation of Maf1, just as S6K1, and 4E-BP1 via the inhibition of mTOR. WYE-132-treated MG63 markedly upregulated the Maf1 amouts in the nucleus. WYE-125132 showed a substantially more effective inhibition in many respects, including cancer cell growth and survival, protein synthesis bioenergetic metabolism, and adaptation to hypoxia by contrast with the rapalog temsirolimus/CCI-779.
| Cell Experiment | |
|---|---|
| Cell lines | WYE-125132 |
| Preparation method | Obtaining cell lines of MDA-MB-361, MDA-MB-231, MDA-MB-468, BT549, LNCap, A549, H1975, H157, H460, U87MG, A498, 786-O, HCT116, MG63, Rat1, HEK293, and HeLa from the American Type Culture Collection. Describing cell growth assays and IC50 determination as follows. For tumor cell growth assays, plating cells in 96-well culture plates at 1000 to 3000 cells per well for 24 hours, treating with DMSO or various doses of WYE-125132. Viable cell densities are determined three days later by MTS assay employing an assay kit following the kit assay protocol.Calculating the effect of each treatment as percent of control growth relative to the DMSO-treated cells grown in the same culture plate. Ploting inhibitor dose response curves for determination of IC50 values. |
| Concentrations | 0 to 10 μM |
| Incubation time | 24 hours |
| Animal Experiment | |
|---|---|
| Animal models | U87MG, MDA361, H1975, A549, A498, and 786-O cells are injected s.c. into the right flank of CD1 nu/nu mice |
| Formulation | WYE-125132 is dissolved in 5% ethanol, 2% Tween 80, and 5% polyethylene glycol-400 |
| Dosages | ≤50 mg/kg |
| Administration | Administered via i.v. or p.o. |
| Molecular Weight | 519.6 |
| Formula | C27H33N7O4 |
| CAS Number | 1144068-46-1 |
| Solubility (25°C) | DMSO 100 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Ying Cong, et al. mTOR Promotes Tissue Factor Expression and Activity in EGFR-Mutant Cancer
[2] Dan Zhang, et al. The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor
| Related mTOR Products |
|---|
| AZD8055
AZD8055 is a novel ATP-competitive inhibitor of mTOR kinase (both complexes mTORC1 and mTORC2) with an IC50 of 0.8 nM. |
| Deforolimus
Deforolimus (also known as AP23573 and MK-8669) is an investigational targeted and small-molecule mTOR inhibitor. *The compound is unstable in solutions, freshly prepared is recommended |
| Everolimus
Everolimus (RAD001) also known as SDZ-RAD and Certican is an mTOR inhibitor with IC50 of 0.63 nM. |
| KU-0063794
KU-0063794 is a potent and selective mTOR inhibitor with IC50 values of approximately 10 nM for mTORC1 and mTORC2. |
| WYE-354
WYE-354 is a cell-permeable pyrazolopyrimidine compound that acts as a potent and ATP-competitive mTOR inhibitor (IC50 = 5 nM with S6K as the substrate and 100 µM ATP). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
